Immune Profiling of Medullary Thyroid Cancer-An Opportunity for Immunotherapy

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Medullary thyroid cancer (MTC) is a rare cancer originating from C-cells, posing treatment challenges, especially in metastatic cases.
• Understanding immune cell inhibition mechanisms in MTC is crucial for developing novel therapeutic strategies.
• The immunological landscape of MTC remains largely unexplored.

Purpose of the Study:

• To investigate the gene expression profile of medullary thyroid cancer.
• To identify potential therapeutic targets by examining immune cell interactions in MTC.
• To explore the role of CD276 in MTC pathogenesis and its correlation with clinical factors.

Main Methods:

• Analysis of gene expression profiles for 395 genes in 51 MTC patients.
• Bioinformatic analysis to compare gene expression in MTC versus normal tissue.
• Correlation analysis between CD276 expression and clinical/histopathological factors.

Main Results:

• CD276 expression was found to be at least three-fold higher in MTC cells compared to normal tissue.
• A weak but significant positive correlation was observed between CD276 expression and tumor diameter.
• No significant association was found between CD276 levels and other clinical factors or treatment response.

Conclusions:

• Elevated CD276 expression in MTC suggests its potential role in immune evasion.
• The monoclonal antibody enoblituzumab is identified as a potential therapeutic agent for MTC patients with high CD276 expression.
• Further research into CD276's function could lead to targeted immunotherapies for medullary thyroid cancer.